ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1644

Safety and Efficacy of ANG-3070 in Patients with Primary Proteinuric Kidney Disease: A Phase 2 Study Design

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Radhakrishnan, Jai, Columbia University Irving Medical Center, New York, New York, United States
  • Aslam, Shakil, Angion Biomedica Corp, Uniondale, New York, United States
  • Neylan, John F., Angion Biomedica Corp, Uniondale, New York, United States
  • Rizk, Dana, University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Trachtman, Howard, NYU Grossman School of Medicine, New York, New York, United States
Background

Primary proteinuric kidney diseases (PPKDs) are among the leading causes of End-Stage Kidney Disease (ESKD). Receptor tyrosine kinases like PDGFR, DDR1, DDR2 are thought to play a role in the progression of PPKDs to ESKD. ANG-3070, a selective oral tyrosine kinase inhibitor, has demonstrated beneficial effects in chronic kidney disease animal models.
Objective: Describe the design of a proof-of-concept study of ANG-3070 in the treatment of PPKD patients with persistent proteinuria while on standard of care (SOC).

Methods

A 12-week, randomized, double-blind, placebo-controlled study enrolling 100 patients with biopsy-proven PPKD and persistent proteinuria, ≥ 1 g/day, while on the SOC including maximum tolerated RAAS inhibitors. Patients will be randomized 1:1:1:1 to 200 mg or 400 mg once-daily or 300 mg twice-daily of ANG-3070 or placebo (Fig.1).

Results

The primary endpoint is the percentage change in 24-hr urinary protein at Week 12. Key secondary endpoints evaluated at week 12 include percentage change in 24-hr urinary albumin, number of patients with complete remission in proteinuria (24-hr urinary protein < 300 mg), number of patients with partial remissions in proteinuria (24-hr urinary protein reduction of ≥ 50% from the baseline and a 24-hr urinary protein < 3.5 g/day if the baseline 24-hr urinary protein > 3.5 g), number of patients with ≥ 50% reduction in 24-hr urinary protein from the baseline, and number of patients with ≥ 50% reduction in 24-hr urinary albumin from baseline. An independent data monitoring committee will review safety throughout the study.

Conclusion

This Phase 2 study will provide data about the safety and efficacy of ANG-3070 in PPKD patients that will inform the design of a Phase 3 study.

Funding

  • Commercial Support